Oversight Committee of the Cancer Prevention and Research Institute of Texas Meeting Minutes
The committee reviewed reports from the CEO, Chief Scientific Officer, Chief Product Development Officer, and Chief Compliance Officer regarding grant award recommendations for academic research and product development programs. Key discussions included appointment approvals for various advisory committees, the adoption of an honoraria policy, the approval of health and safety code waivers, and proposed rule amendments. Additionally, the committee reviewed internal auditor reports, grant management platform modernization updates, and authorized the disbursement of grant funds via advance payments. Financial matters, including the operating budget, bond issuance resolutions, and legislative appropriations requests for the 2028-2029 biennium, were also addressed.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The committee held a presentation by Omni Nano regarding a grantee project focused on developing a drug delivery system for solid tumors, specifically pancreatic cancer. The discussion covered the mechanism of the nano-polymeric drug, its efficacy in pre-clinical studies in penetrating tumor stroma, and its potential to improve therapeutic outcomes by enhancing tumor-specific delivery while reducing systemic exposure. Additionally, the committee received updates on the progress of seed grant goals, including dose optimization, ongoing toxicology studies, and chemical synthesis processes for the drug product.
The committee meeting featured a presentation from a grantee, the CEO of Omni Nano, regarding the development of a therapeutic approach for treating solid tumors, specifically focusing on pancreatic cancer. Discussion points included the mechanism of their nano-medicine drug delivery system, preclinical study results demonstrating tumor concentration and survival benefits, and the company's progress on its seed grant goals, including dose optimization, toxicology studies, and the drug synthesis process.
May 20, 2026·Board meeting
Oversight Committee Meeting
The committee meeting covered a wide range of administrative, compliance, and programmatic topics. These included CEO, compliance, scientific, and product development officer reports, alongside recommendations for academic research and product development grant awards. Discussions also encompassed the appointment of members to various advisory and scientific research committees, proposed amendments to administrative rules, financial status updates, legislative appropriation requests, and bond issuance resolutions. Additionally, the committee addressed internal audit reports, compliance training, and preparations for upcoming conferences.
